BACKGROUND: Protein-truncating mutations in the titin gene are associated with increased risk of atrial fibrillation. However, little is known about the underlying pathophysiology. METHODS: We identified a heterozygous titin truncating variant (TTNtv) in a patient with unexplained early onset atrial fibrillation and normal ventricular function. We generated patient-specific atrial- and ventricular-like induced pluripotent stem cell-derived cardiomyocytes and engineered heart tissue to evaluate the impact of the TTNtv on electrophysiology, sarcomere structure, contractility, and gene expression. RESULTS: We demonstrate that the TTNtv increases susceptibility to pacing-induced arrhythmia, promotes sarcomere disorganization, and reduces contractile force in atrial induced pluripotent stem cell-derived cardiomyocytes compared with their CRISPR/Cas9-corrected isogenic controls. In ventricular induced pluripotent stem cell-derived cardiomyocytes, this variant was associated with abnormal electrophysiology and sarcomere organization without a reduction in contractile force compared with their isogenic controls. RNA-sequencing revealed an upregulation of cell adhesion and extracellular matrix genes in the presence of the TTNtv for both atrial and ventricular engineered heart tissues. CONCLUSIONS: In a patient with unexplained atrial fibrillation, induced pluripotent stem cell-derived cardiomyocytes with a TTNtv showed structural and electrophysiological abnormalities in both atrial and ventricular models, while only atrial engineered heart tissues demonstrated reduced contractility. The observed chamber-specific effect suggests that structural disorganization and reduced contractile function may be associated with atrial myopathy in the presence of truncated titin.
Males and females exhibit intrinsic differences in the structure and function of the heart, while the prevalence and severity of cardiovascular disease vary in the two sexes. However, the mechanisms of this sex-based dimorphism are yet to be elucidated. Sex chromosomes and sex hormones are the main contributors to sex-based differences in cardiac physiology and pathophysiology. In recent years, the advances in induced pluripotent stem cell-derived cardiac models and multi-omic approaches have enabled a more comprehensive understanding of the sex-specific differences in the human heart. Here, we provide an overview of the roles of these two factors throughout cardiac development and explore the sex hormone signaling pathways involved. We will also discuss how the employment of stem cell-based cardiac models and single-cell RNA sequencing help us further investigate sex differences in healthy and diseased hearts.
Background: Engineered heart tissues (EHTs) are widely used for cardiac disease modeling and drug screening, but their lack of multicellularity limits translational relevance. Thus, it is essential to incorporate other cardiac cells to improve the reliability and accuracy of the model. Objectives: To develop a co-culture EHT model from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) and cardiac fibroblasts (CFs) and assess its structural, contractile, electrophysiological and metabolic properties. Methods: hiPSCs were differentiated into CMs and CFs and combined at a ratio of 3:1 to generate co-culture EHTs. Structural, functional and metabolic features of CM-only and co-culture EHTs were evaluated and compared using immunofluorescence, force analysis, optical mapping and metabolomics. Results: Co-culture EHTs were more compact, generated higher force when stimulated, and displayed improved sarcomere organization compared to CM-only EHTs. They showed reduced hypoxia under high frequency pacing and a more mature, stress resistant metabolic profile, while maintaining stable electrophysiology and reduced arrhythmogenicity. Conclusions: Incorporating hiPSC-CFs into EHTs enhanced structural and functional properties, improved stress resistance, and reduced variability, making our co-culture EHTs a more physiological and predictive platform for cardiac disease modeling and drug screening.